Evidence map›Paper›PMID 32160634›Full record

ArticlePloS one2020

Topical dual-probe staining using quantum dot-labeled antibodies for identifying tumor biomarkers in fresh specimens.

Boyu Meng, Margaret R Folaron, Brook K Byrd, Kimberley S Samkoe, Rendall S Strawbridge, Connor Barth, Summer L Gibbs, Scott C Davis

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Theranostics · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Boyu MengThayer School of Engineering at Dartmouth College, Hanover, New Hampshire, United States of America.ORCID 0000-0003-1418-5459
Margaret R FolaronThayer School of Engineering at Dartmouth College, Hanover, New Hampshire, United States of America.
Brook K ByrdThayer School of Engineering at Dartmouth College, Hanover, New Hampshire, United States of America.
Kimberley S SamkoeGeisel School of Medicine at Dartmouth College, Hanover, New Hampshire, United States of America.
Rendall S StrawbridgeThayer School of Engineering at Dartmouth College, Hanover, New Hampshire, United States of America.
Connor BarthBiomedical Engineering Department, Oregon Health and Science University, Portland, Oregon, United States of America.ORCID 0000-0002-6235-7238
Summer L GibbsBiomedical Engineering Department, Oregon Health and Science University, Portland, Oregon, United States of America.
Scott C DavisThayer School of Engineering at Dartmouth College, Hanover, New Hampshire, United States of America.
Dartmouth College · USOregon Health & Science University · US

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
Multi-probe fluorescence imaging for rapid intra-operative tumor margin assessmentR01CA188491 · NCI · DARTMOUTH COLLEGE · PI DAVIS, SCOTT C · 2015 to 2019
$2.9M
MRI fluorescence tomography for quantifying tumor receptor concentration in vivoR01CA184354 · NCI · DARTMOUTH COLLEGE · PI DAVIS, SCOTT C · 2014 to 2018
$2.6M
NCI NIH HHS P30 CA023108NCI NIH HHS R01 CA184354NCI NIH HHS R01 CA188491
6 · The paper itself

Abstract

purposeRapid, intra-operative identification of tumor tissue in the margins of excised specimens has become an important focus in the pursuit of reducing re-excision rates, especially for breast conserving surgery. Dual-probe difference specimen imaging (DDSI) is an emerging approach that uses the difference in uptake/clearance kinetics between a pair of fluorescently-labeled stains, one targeted to a biomarker-of-interest and the other an untargeted isotype, to reveal receptor-specific images of the specimen. Previous studies using antibodies labeled with either enhanced Raman particles or organic fluorophores have shown promising tumor vs. normal diagnostic performance. Yet, the unique properties of quantum dot-labeled antibody complexes (QDACs), which provide spectrally-distinct fluorescence emission from a common excitation source, make them ideal candidates for this application. Herein, we evaluate the diagnostic performance of QDAC-based DDSI in excised xenografts. PROCEDURES: Excised fresh specimens of normal tissue and human tumor xenografts with elevated expression of HER2 were stained with a HER2-targeted QDAC and an untargeted QDAC isotype. Stained specimens were imaged on a custom hyperspectral imaging system capable of spectrally separating the quantum dot signatures, and images processed using the DDSI approach. The diagnostic performance of this technique under different incubation temperatures and probe concentrations was evaluated using receiver-operator characteristic analysis.

resultsHER2-targeted QDAC-DDSI was able to distinguish HER2(+) tumors from normal tissue with reasonably high diagnostic performance; however, this performance was sensitive to temperature during the staining procedure. Area under the curve values were 0.61 when staining at room temperature but increased to over 0.81 when staining at 37 °C. Diagnostic performance was not affected by increasing stain concentration.

conclusionsThis study is the first to report dual-probe difference imaging of specimens using QDACs and hyperspectral imaging. Our results show promising diagnostic performance under certain conditions, and compel further optimization and evaluation of this intra-operative margin assessment technique.

Indexed as

Quantum DotsAnimalsAntibodiesBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunoassayMammary Neoplasms, ExperimentalMCF-7 CellsMiceMice, NudeMicroscopy, FluorescenceAntibodiesBiomarkers, TumorErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID32160634
PMCPMC7065915
OpenAlexW3012091821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.